Biosimilars: Novel Emerging Field of Biomedicine
DOI:
https://doi.org/10.37285/ijpsn.2021.14.5.2Abstract
A biosimilar is the new emerging drug product of the sector of Biologics that comes under speedily evolving area of pharmaceutical industry. It is the generic substitute for original research-based drugs. Since the Biologics are produced by a variety of products more commonly including cells extracted from humans, animals, microorganisms which varies phenotypically therefore they are “similar but not same” to the original product. Being a new product, it produces several challenges in the market including its regulation guidelines, production efficiency, quality management, and safety factors etc. The quality of these products along with its effectiveness and reduced costs are making them more and more popular. Different research is still being going on for enhancing the efficacy of biosimilars due to its more and more usage in the market. Several countries have developed their separate norms for the production and clinical usage of these biosimilars constituting Canada, Japan, Korea, and United States of America etc. The more biologics grab the attention of the eminent scientists for better innovations, the less marketing approval it gets. To enhance such a situation U S Congress passed the Biologics Price Competition and Innovation act 2009 and US FDA allowed “abbreviated pathway” for their approval and India being the most suited manufacturing area has also prepared certain guidelines stated as “Draft Guidelines on Similar Biologics” which were announced in June 2012, by Department of Biotechnology at Boston bio. The regulatory environment for biosimilars continues to evolve, both in recognition of advances in technology/ analytical methods and the availability of new targets for biosimilar development. With the advent of such efforts biosimilars are trying to surround the market. The demanding sector of biosimilars reveals the challenging gateway towards the nanomedicines also which shows that with the advancing biotechnology after these biosimilars, we are heading towards other newly biologically derived products.
Downloads
Metrics
Keywords:
Biosimilar, Biologics, Omnitrope, Pharmacodynamics, Immunogenicity
Downloads
Published
How to Cite
Issue
Section
References
Aapro, M., Krendyukov, A., Höbel, N., Seidl, A., & Gascón, P. (2018). Development and 10-year history of a biosimilar: the example of Binocrit®. Therapeutic advances in medical oncology, 10, 1758835918768419.
Agostini, C., Canonica, G. W., & Maggi, E. (2015). European medicines agency guideline for biological medicinal products: a further step for a safe use of biosimilars.
Akhtar, N., Joshi, A., Kaushik, V., Kumar, M., & Mannan, M. A. U. (2021). In-silico design of a multivalent epitope-based vaccine against Candida auris. Microbial Pathogenesis, 155: 104879.
Akhtar, N., Joshi, A., Singh, B., & Kaushik, V. (2020). Immuno-Informatics Quest against COVID-19/SARS-COV-2: Determining Putative T-Cell Epitopes for Vaccine Prediction. Infectious Disorders Drug Targets.
Alten, R., &Cronstein, B. N. (2015, June). Clinical trial development for biosimilars. In Seminars in arthritis and rheumatism (Vol. 44, No. 6, pp. S2-S8).
Amgen Biosimilars (2021) Available
from: https://www.amgenscience.com/biosimilar-research-and-development/. (Accessed April 10, 2021)
Brooks, S. A. (2004). Appropriate glycosylation of recombinant proteins for human use. Molecular biotechnology, 28(3): 241-255.
Buffery, D. (2010). Competition from biosimilars an incentive for innovation. American health & drug benefits, 3(1): 27.
Casadevall, N. (2003). Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrology Dialysis Transplantation, 18(suppl_8), viii37-viii41.
Chopra, R., & Lopes, G. (2017). Improving access to cancer treatments: the role of biosimilars. Journal of global oncology, 3(5): 596-610.
Cohen, A. D., Wu, J. J., Puig, L., Chimenti, S., Vender, R., Rajagopalan, M., ... & Blauvelt, A. (2017). Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. British Journal of Dermatology, 177(6): 1495-1502
Gerrard, T. L., Johnston, G., &Gaugh, D. R. (2015). Biosimilars: extrapolation of clinical use to other indications. GaBI J, 4(3): 118-24.
Giezen, T. J., & Schneider, C. K. (2014). Safety assessment of biosimilars in Europe: a regulatory perspective. Generics Biosimilars Initiat J, 3: 180-3.
Grabowski, H. G., Guha, R., & Salgado, M. (2014). Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future. Health Affairs, 33(6): 1048-1057.
G, S. K., Joshi, A., & Kaushik, V. (2020). T cell epitope designing for dengue peptide vaccine using docking and molecular simulation studies. Molecular Simulation, 46(10): 787–795.
Haag-Weber, M., Eckardt, K. U., Hürl, W. H., Roger, S. D., Vetter, A., & Roth, K. (2012). Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clinical nephrology, 77(1).
Hofmarcher, T., Jönsson, B., &Wilking, N. (2013). Access to high-quality oncology care across Europe. IHE.
IMS Health report. The impact on biosimilar competition; 2021. Available from: http://ec.europa.eu/DocsRoom/documents/14547/attachments/1/translations/en/renditions/native. Accessed April 10, 2021.
Joshi, A., Joshi, B. C., Mannan, M. A. U., & Kaushik, V. (2020a). Epitope based vaccine prediction for SARS-COV-2 by deploying immuno-informatics approach. Informatics in medicine unlocked, 19: 100338.
Joshi, A., & Kaushik, V. (2020). In-silico proteomic exploratory quest: crafting T-cell epitope vaccine against Whipple’s disease. International journal of peptide research and therapeutics, 1-11.
Kim, H., Alten, R., Avedano, L., Dignass, A., Gomollón, F., Greveson, K., ... & Jeong, J. H. (2020). The future of biosimilars: Maximizing benefits across immune-mediated inflammatory diseases. Drugs, 80(2): 99-113.
Krishnan G, S., Joshi, A., Akhtar, N., & Kaushik, V. (2021). Immunoinformatics designed T cell multi epitope dengue peptide vaccine derived from non structuralproteome. Microbial Pathogenesis, 150: 104728.
Mestre-Ferrandiz, J., Towse, A., & Berdud, M. (2016). Biosimilars: how can payers get long-term savings? Pharmaco-economics, 34(6): 609-616.
Mulcahy, A. W., Predmore, Z., & Mattke, S. (2014). The cost savings potential of biosimilar drugs in the United States. Perspectives, 1: 1-16.
Omnitrope, European Public Assessment Report, 12 April 2006. Available
from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000607/WC500043692.pdf. (Accessed April 10, 2021).
Pfizer Biosimilars. (2021). Available
From: http://www.pfizer.com/research/science_and_technology/biosimilars. (Accessed April 10, 2021)
Putrik, P., Ramiro, S., Kvien, T. K., Sokka, T., Pavlova, M., Uhlig, T., & Boonen, A. (2014). Working Group ‘Equity in access to treatment of rheumatoid arthritis in Europe’Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis, 73(1): 198-206.
Roger, S. D., & Mikhail, A. (2007). Biosimilars: opportunity or cause for concern. J Pharm Pharm Sci, 10(3): 405-410.
Schell kens H.The immunogenicity of therapeutic proteins Discovered med. 2010; 9(49): 560-4
Stebbing, J., Mainwaring, P. N., Curigliano, G., Pegram, M., Latymer, M., Bair, A. H., &Rugo, H. S. (2020). Understanding the role of comparative clinical studies in the development of oncology biosimilars. Journal of Clinical Oncology, 38(10): 1070.
